Skip to main content

Table 1 Response and time to progression in randomized trials comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy or in advanced breast cancer

From: Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Reference

Agent administered

Number of subjects

Response(%)

Clinical benefit(%)

Time to progression(months)

[9]

Letrozole

453

30

49

9.4

 

Tamoxifen

454

20

38

6.0

[13]

Letrozole

154

55

-

-

 

Tamoxifen

170

36

-

-

[11]

Anastrozole

171

21

59

11.1

 

Tamoxifen

182

17

46

5.6

[19]

Anastrozole

340

33

56

8.2

 

Tamoxifen

328

33

56

8.3

[11]

Anastrozole

121

43

83

-

 

Tamoxifen

117

31

56

-

[10]

Exemestane

61

41

57

-

 

Tamoxifen

59

17

42

-